Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed250%
unknown250%

Recent Activity

0 active trials
Showing 4 of 4
unknown

Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial

NCT04580992
unknownphase_2

The Response To Ajmaline Provocation in Healthy Subjects

NCT02933437
completednot_applicable

Epicardial Ablation in Brugada Syndrome

NCT02641431
completedphase_4

Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias

NCT00702117

Clinical Trials (4)

Showing 4 of 4 trials
NCT04580992

Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial

Unknown
NCT02933437Phase 2

The Response To Ajmaline Provocation in Healthy Subjects

Unknown
NCT02641431Not Applicable

Epicardial Ablation in Brugada Syndrome

Completed
NCT00702117Phase 4

Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4